The global HER2 ADC Drugs for Cancer market was valued at US$ 7794 million in 2025 and is anticipated to reach US$ 13788 million by 2032, at a CAGR of 8.2% from 2026 to 2032.

HER2 ADC Drugs for Cancer Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on HER2 ADC Drugs for Cancer competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

In 2025, global HER2 ADC Drugs for Cancer reached approximately 7.27 M Units, with an average global market price of around 1071 USD per Unit.

HER2 ADC Drugs for Cancer (HER2-targeted antibody–drug conjugates) are a class of targeted cancer medicines that use an anti-HER2 monoclonal antibody to recognize and bind tumor cells with HER2 overexpression, amplification, or certain HER2-driven biology, and then deliver a highly potent cytotoxic payload into (and sometimes around) those cells. Structurally, they are built from three essential parts: (1) the HER2 antibody (the “homing” component), (2) a chemical linker (designed to be stable in blood but release the payload under specific conditions), and (3) the payload (a cell-killing drug such as a microtubule inhibitor or topoisomerase I inhibitor). After binding HER2, the ADC is typically internalized and processed so the payload can be released to damage critical cellular machinery and trigger cancer cell death; depending on the payload/linker properties, some HER2 ADCs can also produce a bystander effect, meaning the released payload may diffuse to kill nearby tumor cells that have lower HER2 expression.

HER2 ADC Drugs for Cancer fuse the validated targeting precision of anti-HER2 antibodies with the tumor-killing power of highly potent payloads, offering a pragmatic way to overcome two persistent oncology pain points at once: the limited durability of benefit from many standard targeted agents once resistance emerges, and the systemic toxicity that often constrains conventional chemotherapy. By using HER2 as a delivery address, these conjugates can concentrate cytotoxic exposure inside cancer cells and—depending on linker and payload design—extend activity into heterogeneous tumors through bystander killing, which is increasingly important as clinicians recognize that clinically meaningful HER2 biology exists beyond the classic “HER2-positive” bucket. Looking forward, the category’s market potential is supported by broad applicability across major solid tumors, steady innovation that improves therapeutic index through smarter linkers, controlled conjugation, and next-generation payloads, and the likelihood that HER2 ADCs will become central “backbone” options that can be sequenced with, or paired alongside, endocrine therapy, immunotherapy, and other targeted agents—positioning the space for sustained expansion without relying on unrealistic expectations.

The core raw materials for HER2 ADC Drugs for Cancer mainly include anti-HER2 antibodies, linkers, and auxiliary materials. Typical suppliers include Roche, Daiichi Sankyo, Merck, Thermo Fisher, etc. The downstream applications are mainly in the treatment of diseases such as breast cancer.

The production capacity of HER2 ADC Drugs for Cancer varies greatly depending on the antibody production, conjugation process, quality control, and supply chain support. The gross profit margin of HER2 ADC Drugs for Cancer is in the range of 70%-80%.

The North American market for HER2 ADC Drugs for Cancer is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for HER2 ADC Drugs for Cancer is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

Major global manufacturers of HER2 ADC Drugs for Cancer include Roche, AstraZeneca, Daiichi Sankyo, Remegen, Jiangsu Hengrui Medicine, Shanghai Henlius Biotech, Sichuan Kelun-Biotech Biopharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global HER2 ADC Drugs for Cancer market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding HER2 ADC Drugs for Cancer. The HER2 ADC Drugs for Cancer market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global HER2 ADC Drugs for Cancer market comprehensively. Regional market sizes by Type, by Application, by HER2 Expression Level, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist HER2 ADC Drugs for Cancer manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of HER2 ADC Drugs for Cancer Market Report

Report Metric	Details
Report Name	HER2 ADC Drugs for Cancer Market
Accounted market size in 2025	US$ 7794 million
Forecasted market size in 2032	US$ 13788 million
CAGR	8.2%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Trastuzumab Type Non-trastuzumab Type
Segment by HER2 Expression Level	HER2 Positive HER2 Low Expression
Segment by Antibody	Monoclonal Antibody Bispecific Antibody Others
by Application	Breast Cancer Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Roche, AstraZeneca, Daiichi Sankyo, Remegen, Jiangsu Hengrui Medicine, Shanghai Henlius Biotech, Sichuan Kelun-Biotech Biopharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by HER2 Expression Level, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for HER2 ADC Drugs for Cancer manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines HER2 ADC Drugs for Cancer sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is HER2 ADC Drugs for Cancer Market growing?

Ans: The HER2 ADC Drugs for Cancer Market witnessing a CAGR of 8.2% during the forecast period 2026-2032.

What is the HER2 ADC Drugs for Cancer Market size in 2032?

Ans: The HER2 ADC Drugs for Cancer Market size in 2032 will be US$ 13788 million.

Who are the main players in the HER2 ADC Drugs for Cancer Market report?

Ans: The main players in the HER2 ADC Drugs for Cancer Market are Roche, AstraZeneca, Daiichi Sankyo, Remegen, Jiangsu Hengrui Medicine, Shanghai Henlius Biotech, Sichuan Kelun-Biotech Biopharmaceutical

What are the Application segmentation covered in the HER2 ADC Drugs for Cancer Market report?

Ans: The Applications covered in the HER2 ADC Drugs for Cancer Market report are Breast Cancer, Others

What are the Type segmentation covered in the HER2 ADC Drugs for Cancer Market report?

Ans: The Types covered in the HER2 ADC Drugs for Cancer Market report are Trastuzumab Type, Non-trastuzumab Type

1 HER2 ADC Drugs for Cancer Market Overview

1.1 Product Definition

1.2 HER2 ADC Drugs for Cancer by Type

1.2.1 Global HER2 ADC Drugs for Cancer Market Value by Type: 2025 vs 2032

1.2.2 Trastuzumab Type

1.2.3 Non-trastuzumab Type

1.3 HER2 ADC Drugs for Cancer by HER2 Expression Level

1.3.1 Global HER2 ADC Drugs for Cancer Market Value by HER2 Expression Level: 2025 vs 2032

1.3.2 HER2 Positive

1.3.3 HER2 Low Expression

1.4 HER2 ADC Drugs for Cancer by Antibody

1.4.1 Global HER2 ADC Drugs for Cancer Market Value by Antibody: 2025 vs 2032

1.4.2 Monoclonal Antibody

1.4.3 Bispecific Antibody

1.4.4 Others

1.5 HER2 ADC Drugs for Cancer by Application

1.5.1 Global HER2 ADC Drugs for Cancer Market Value by Application: 2025 vs 2032

1.5.2 Breast Cancer

1.5.3 Others

1.6 Global HER2 ADC Drugs for Cancer Market Size Estimates and Forecasts

1.6.1 Global HER2 ADC Drugs for Cancer Revenue 2021–2032

1.6.2 Global HER2 ADC Drugs for Cancer Sales 2021–2032

1.6.3 Global HER2 ADC Drugs for Cancer Market Average Price (2021–2032)

1.7 Assumptions and Limitations

2 HER2 ADC Drugs for Cancer Market Competition by Manufacturers

2.1 Global HER2 ADC Drugs for Cancer Sales Market Share by Manufacturers (2021–2026)

2.2 Global HER2 ADC Drugs for Cancer Revenue Market Share by Manufacturers (2021–2026)

2.3 Global HER2 ADC Drugs for Cancer Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of HER2 ADC Drugs for Cancer, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of HER2 ADC Drugs for Cancer, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of HER2 ADC Drugs for Cancer, Product Types and Applications

2.7 Global Key Manufacturers of HER2 ADC Drugs for Cancer, Date of Entry into the Industry

2.8 Global HER2 ADC Drugs for Cancer Market Competitive Situation and Trends

2.8.1 Global HER2 ADC Drugs for Cancer Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global HER2 ADC Drugs for Cancer Players Market Share by Revenue

2.8.3 Global HER2 ADC Drugs for Cancer Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global HER2 ADC Drugs for Cancer Market Scenario by Region

3.1 Global HER2 ADC Drugs for Cancer Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global HER2 ADC Drugs for Cancer Sales by Region: 2021–2032

3.2.1 Global HER2 ADC Drugs for Cancer Sales by Region: 2021–2026

3.2.2 Global HER2 ADC Drugs for Cancer Sales by Region: 2027–2032

3.3 Global HER2 ADC Drugs for Cancer Revenue by Region: 2021–2032

3.3.1 Global HER2 ADC Drugs for Cancer Revenue by Region: 2021–2026

3.3.2 Global HER2 ADC Drugs for Cancer Revenue by Region: 2027–2032

3.4 North America HER2 ADC Drugs for Cancer Market Facts & Figures by Country

3.4.1 North America HER2 ADC Drugs for Cancer Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America HER2 ADC Drugs for Cancer Sales by Country (2021–2032)

3.4.3 North America HER2 ADC Drugs for Cancer Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe HER2 ADC Drugs for Cancer Market Facts & Figures by Country

3.5.1 Europe HER2 ADC Drugs for Cancer Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe HER2 ADC Drugs for Cancer Sales by Country (2021–2032)

3.5.3 Europe HER2 ADC Drugs for Cancer Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific HER2 ADC Drugs for Cancer Market Facts & Figures by Region

3.6.1 Asia Pacific HER2 ADC Drugs for Cancer Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific HER2 ADC Drugs for Cancer Sales by Region (2021–2032)

3.6.3 Asia Pacific HER2 ADC Drugs for Cancer Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America HER2 ADC Drugs for Cancer Market Facts & Figures by Country

3.7.1 Latin America HER2 ADC Drugs for Cancer Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America HER2 ADC Drugs for Cancer Sales by Country (2021–2032)

3.7.3 Latin America HER2 ADC Drugs for Cancer Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa HER2 ADC Drugs for Cancer Market Facts & Figures by Country

3.8.1 Middle East and Africa HER2 ADC Drugs for Cancer Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa HER2 ADC Drugs for Cancer Sales by Country (2021–2032)

3.8.3 Middle East and Africa HER2 ADC Drugs for Cancer Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global HER2 ADC Drugs for Cancer Sales by Type (2021–2032)

4.1.1 Global HER2 ADC Drugs for Cancer Sales by Type (2021–2026)

4.1.2 Global HER2 ADC Drugs for Cancer Sales by Type (2027–2032)

4.1.3 Global HER2 ADC Drugs for Cancer Sales Market Share by Type (2021–2032)

4.2 Global HER2 ADC Drugs for Cancer Revenue by Type (2021–2032)

4.2.1 Global HER2 ADC Drugs for Cancer Revenue by Type (2021–2026)

4.2.2 Global HER2 ADC Drugs for Cancer Revenue by Type (2027–2032)

4.2.3 Global HER2 ADC Drugs for Cancer Revenue Market Share by Type (2021–2032)

4.3 Global HER2 ADC Drugs for Cancer Price by Type (2021–2032)

5 Segment by Application

5.1 Global HER2 ADC Drugs for Cancer Sales by Application (2021–2032)

5.1.1 Global HER2 ADC Drugs for Cancer Sales by Application (2021–2026)

5.1.2 Global HER2 ADC Drugs for Cancer Sales by Application (2027–2032)

5.1.3 Global HER2 ADC Drugs for Cancer Sales Market Share by Application (2021–2032)

5.2 Global HER2 ADC Drugs for Cancer Revenue by Application (2021–2032)

5.2.1 Global HER2 ADC Drugs for Cancer Revenue by Application (2021–2026)

5.2.2 Global HER2 ADC Drugs for Cancer Revenue by Application (2027–2032)

5.2.3 Global HER2 ADC Drugs for Cancer Revenue Market Share by Application (2021–2032)

5.3 Global HER2 ADC Drugs for Cancer Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Roche

6.1.1 Roche Company Information

6.1.2 Roche Description and Business Overview

6.1.3 Roche HER2 ADC Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Roche HER2 ADC Drugs for Cancer Product Portfolio

6.1.5 Roche Recent Developments/Updates

6.2 AstraZeneca

6.2.1 AstraZeneca Company Information

6.2.2 AstraZeneca Description and Business Overview

6.2.3 AstraZeneca HER2 ADC Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 AstraZeneca HER2 ADC Drugs for Cancer Product Portfolio

6.2.5 AstraZeneca Recent Developments/Updates

6.3 Daiichi Sankyo

6.3.1 Daiichi Sankyo Company Information

6.3.2 Daiichi Sankyo Description and Business Overview

6.3.3 Daiichi Sankyo HER2 ADC Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Daiichi Sankyo HER2 ADC Drugs for Cancer Product Portfolio

6.3.5 Daiichi Sankyo Recent Developments/Updates

6.4 Remegen

6.4.1 Remegen Company Information

6.4.2 Remegen Description and Business Overview

6.4.3 Remegen HER2 ADC Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Remegen HER2 ADC Drugs for Cancer Product Portfolio

6.4.5 Remegen Recent Developments/Updates

6.5 Jiangsu Hengrui Medicine

6.5.1 Jiangsu Hengrui Medicine Company Information

6.5.2 Jiangsu Hengrui Medicine Description and Business Overview

6.5.3 Jiangsu Hengrui Medicine HER2 ADC Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Jiangsu Hengrui Medicine HER2 ADC Drugs for Cancer Product Portfolio

6.5.5 Jiangsu Hengrui Medicine Recent Developments/Updates

6.6 Shanghai Henlius Biotech

6.6.1 Shanghai Henlius Biotech Company Information

6.6.2 Shanghai Henlius Biotech Description and Business Overview

6.6.3 Shanghai Henlius Biotech HER2 ADC Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Shanghai Henlius Biotech HER2 ADC Drugs for Cancer Product Portfolio

6.6.5 Shanghai Henlius Biotech Recent Developments/Updates

6.7 Sichuan Kelun-Biotech Biopharmaceutical

6.7.1 Sichuan Kelun-Biotech Biopharmaceutical Company Information

6.7.2 Sichuan Kelun-Biotech Biopharmaceutical Description and Business Overview

6.7.3 Sichuan Kelun-Biotech Biopharmaceutical HER2 ADC Drugs for Cancer Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Sichuan Kelun-Biotech Biopharmaceutical HER2 ADC Drugs for Cancer Product Portfolio

6.7.5 Sichuan Kelun-Biotech Biopharmaceutical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 HER2 ADC Drugs for Cancer Industry Chain Analysis

7.2 HER2 ADC Drugs for Cancer Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 HER2 ADC Drugs for Cancer Production Mode & Process Analysis

7.4 HER2 ADC Drugs for Cancer Sales and Marketing

7.4.1 HER2 ADC Drugs for Cancer Sales Channels

7.4.2 HER2 ADC Drugs for Cancer Distributors

7.5 HER2 ADC Drugs for Cancer Customer Analysis

8 HER2 ADC Drugs for Cancer Market Dynamics

8.1 HER2 ADC Drugs for Cancer Industry Trends

8.2 HER2 ADC Drugs for Cancer Market Drivers

8.3 HER2 ADC Drugs for Cancer Market Challenges

8.4 HER2 ADC Drugs for Cancer Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Jiangsu Hengrui Medicine

Shanghai Henlius Biotech

Sichuan Kelun-Biotech Biopharmaceutical

List of Tables

Table 1. Global HER2 ADC Drugs for Cancer Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global HER2 ADC Drugs for Cancer Market Value by HER2 Expression Level (US$ Million), 2025 vs 2032

Table 3. Global HER2 ADC Drugs for Cancer Market Value by Antibody (US$ Million), 2025 vs 2032

Table 4. Global HER2 ADC Drugs for Cancer Market Value by Application (US$ Million), 2025 vs 2032

Table 5. Global HER2 ADC Drugs for Cancer Market Competitive Situation by Manufacturers in 2025

Table 6. Global HER2 ADC Drugs for Cancer Sales (K Units) of Key Manufacturers (2021–2026)

Table 7. Global HER2 ADC Drugs for Cancer Sales Market Share by Manufacturers (2021–2026)

Table 8. Global HER2 ADC Drugs for Cancer Revenue (US$ Million) by Manufacturers (2021–2026)

Table 9. Global HER2 ADC Drugs for Cancer Revenue Share by Manufacturers (2021–2026)

Table 10. Global Market HER2 ADC Drugs for Cancer Average Price (US$/Unit) of Key Manufacturers (2021–2026)

Table 11. Global Key Players of HER2 ADC Drugs for Cancer, Industry Ranking, 2023 vs 2024 vs 2025

Table 12. Global Key Manufacturers of HER2 ADC Drugs for Cancer, Manufacturing Sites and Headquarters

Table 13. Global Key Manufacturers of HER2 ADC Drugs for Cancer, Product Types and Applications

Table 14. Global Key Manufacturers of HER2 ADC Drugs for Cancer, Date of Entry into the Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global HER2 ADC Drugs for Cancer Companies by Tier (Tier 1, Tier 2, Tier 3), based on HER2 ADC Drugs for Cancer Revenue, 2025

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global HER2 ADC Drugs for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 19. Global HER2 ADC Drugs for Cancer Sales by Region (K Units), 2021–2026

Table 20. Global HER2 ADC Drugs for Cancer Sales Market Share by Region (2021–2026)

Table 21. Global HER2 ADC Drugs for Cancer Sales by Region (K Units), 2027–2032

Table 22. Global HER2 ADC Drugs for Cancer Sales Market Share by Region (2027–2032)

Table 23. Global HER2 ADC Drugs for Cancer Revenue by Region (US$ Million), 2021–2026

Table 24. Global HER2 ADC Drugs for Cancer Revenue Market Share by Region (2021–2026)

Table 25. Global HER2 ADC Drugs for Cancer Revenue by Region (US$ Million), 2027–2032

Table 26. Global HER2 ADC Drugs for Cancer Revenue Market Share by Region (2027–2032)

Table 27. North America HER2 ADC Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 28. North America HER2 ADC Drugs for Cancer Sales by Country (K Units), 2021–2026

Table 29. North America HER2 ADC Drugs for Cancer Sales by Country (K Units), 2027–2032

Table 30. North America HER2 ADC Drugs for Cancer Revenue by Country (US$ Million), 2021–2026

Table 31. North America HER2 ADC Drugs for Cancer Revenue by Country (US$ Million), 2027–2032

Table 32. Europe HER2 ADC Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 33. Europe HER2 ADC Drugs for Cancer Sales by Country (K Units), 2021–2026

Table 34. Europe HER2 ADC Drugs for Cancer Sales by Country (K Units), 2027–2032

Table 35. Europe HER2 ADC Drugs for Cancer Revenue by Country (US$ Million), 2021–2026

Table 36. Europe HER2 ADC Drugs for Cancer Revenue by Country (US$ Million), 2027–2032

Table 37. Asia Pacific HER2 ADC Drugs for Cancer Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 38. Asia Pacific HER2 ADC Drugs for Cancer Sales by Region (K Units), 2021–2026

Table 39. Asia Pacific HER2 ADC Drugs for Cancer Sales by Region (K Units), 2027–2032

Table 40. Asia Pacific HER2 ADC Drugs for Cancer Revenue by Region (US$ Million), 2021–2026

Table 41. Asia Pacific HER2 ADC Drugs for Cancer Revenue by Region (US$ Million), 2027–2032

Table 42. Latin America HER2 ADC Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 43. Latin America HER2 ADC Drugs for Cancer Sales by Country (K Units), 2021–2026

Table 44. Latin America HER2 ADC Drugs for Cancer Sales by Country (K Units), 2027–2032

Table 45. Latin America HER2 ADC Drugs for Cancer Revenue by Country (US$ Million), 2021–2026

Table 46. Latin America HER2 ADC Drugs for Cancer Revenue by Country (US$ Million), 2027–2032

Table 47. Middle East and Africa HER2 ADC Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 48. Middle East and Africa HER2 ADC Drugs for Cancer Sales by Country (K Units), 2021–2026

Table 49. Middle East and Africa HER2 ADC Drugs for Cancer Sales by Country (K Units), 2027–2032

Table 50. Middle East and Africa HER2 ADC Drugs for Cancer Revenue by Country (US$ Million), 2021–2026

Table 51. Middle East and Africa HER2 ADC Drugs for Cancer Revenue by Country (US$ Million), 2027–2032

Table 52. Global HER2 ADC Drugs for Cancer Sales (K Units) by Type (2021–2026)

Table 53. Global HER2 ADC Drugs for Cancer Sales (K Units) by Type (2027–2032)

Table 54. Global HER2 ADC Drugs for Cancer Sales Market Share by Type (2021–2026)

Table 55. Global HER2 ADC Drugs for Cancer Sales Market Share by Type (2027–2032)

Table 56. Global HER2 ADC Drugs for Cancer Revenue (US$ Million) by Type (2021–2026)

Table 57. Global HER2 ADC Drugs for Cancer Revenue (US$ Million) by Type (2027–2032)

Table 58. Global HER2 ADC Drugs for Cancer Revenue Market Share by Type (2021–2026)

Table 59. Global HER2 ADC Drugs for Cancer Revenue Market Share by Type (2027–2032)

Table 60. Global HER2 ADC Drugs for Cancer Price (US$/Unit) by Type (2021–2026)

Table 61. Global HER2 ADC Drugs for Cancer Price (US$/Unit) by Type (2027–2032)

Table 62. Global HER2 ADC Drugs for Cancer Sales (K Units) by Application (2021–2026)

Table 63. Global HER2 ADC Drugs for Cancer Sales (K Units) by Application (2027–2032)

Table 64. Global HER2 ADC Drugs for Cancer Sales Market Share by Application (2021–2026)

Table 65. Global HER2 ADC Drugs for Cancer Sales Market Share by Application (2027–2032)

Table 66. Global HER2 ADC Drugs for Cancer Revenue (US$ Million) by Application (2021–2026)

Table 67. Global HER2 ADC Drugs for Cancer Revenue (US$ Million) by Application (2027–2032)

Table 68. Global HER2 ADC Drugs for Cancer Revenue Market Share by Application (2021–2026)

Table 69. Global HER2 ADC Drugs for Cancer Revenue Market Share by Application (2027–2032)

Table 70. Global HER2 ADC Drugs for Cancer Price (US$/Unit) by Application (2021–2026)

Table 71. Global HER2 ADC Drugs for Cancer Price (US$/Unit) by Application (2027–2032)

Table 72. Roche Company Information

Table 73. Roche Description and Business Overview

Table 74. Roche HER2 ADC Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 75. Roche HER2 ADC Drugs for Cancer Product

Table 76. Roche Recent Developments/Updates

Table 77. AstraZeneca Company Information

Table 78. AstraZeneca Description and Business Overview

Table 79. AstraZeneca HER2 ADC Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 80. AstraZeneca HER2 ADC Drugs for Cancer Product

Table 81. AstraZeneca Recent Developments/Updates

Table 82. Daiichi Sankyo Company Information

Table 83. Daiichi Sankyo Description and Business Overview

Table 84. Daiichi Sankyo HER2 ADC Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 85. Daiichi Sankyo HER2 ADC Drugs for Cancer Product

Table 86. Daiichi Sankyo Recent Developments/Updates

Table 87. Remegen Company Information

Table 88. Remegen Description and Business Overview

Table 89. Remegen HER2 ADC Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 90. Remegen HER2 ADC Drugs for Cancer Product

Table 91. Remegen Recent Developments/Updates

Table 92. Jiangsu Hengrui Medicine Company Information

Table 93. Jiangsu Hengrui Medicine Description and Business Overview

Table 94. Jiangsu Hengrui Medicine HER2 ADC Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 95. Jiangsu Hengrui Medicine HER2 ADC Drugs for Cancer Product

Table 96. Jiangsu Hengrui Medicine Recent Developments/Updates

Table 97. Shanghai Henlius Biotech Company Information

Table 98. Shanghai Henlius Biotech Description and Business Overview

Table 99. Shanghai Henlius Biotech HER2 ADC Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 100. Shanghai Henlius Biotech HER2 ADC Drugs for Cancer Product

Table 101. Shanghai Henlius Biotech Recent Developments/Updates

Table 102. Sichuan Kelun-Biotech Biopharmaceutical Company Information

Table 103. Sichuan Kelun-Biotech Biopharmaceutical Description and Business Overview

Table 104. Sichuan Kelun-Biotech Biopharmaceutical HER2 ADC Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 105. Sichuan Kelun-Biotech Biopharmaceutical HER2 ADC Drugs for Cancer Product

Table 106. Sichuan Kelun-Biotech Biopharmaceutical Recent Developments/Updates

Table 107. Key Raw Materials Lists

Table 108. Raw Materials Key Suppliers Lists

Table 109. HER2 ADC Drugs for Cancer Distributors List

Table 110. HER2 ADC Drugs for Cancer Customers List

Table 111. HER2 ADC Drugs for Cancer Market Trends

Table 112. HER2 ADC Drugs for Cancer Market Drivers

Table 113. HER2 ADC Drugs for Cancer Market Challenges

Table 114. HER2 ADC Drugs for Cancer Market Restraints

Table 115. Research Programs/Design for This Report

Table 116. Key Data Information from Secondary Sources

Table 117. Key Data Information from Primary Sources

Table 118. Authors List of This Report

List of Figures

Figure 1. Product Picture of HER2 ADC Drugs for Cancer

Figure 2. Global HER2 ADC Drugs for Cancer Market Value by Type (US$ Million), 2021–2032

Figure 3. Global HER2 ADC Drugs for Cancer Market Share by Type: 2025 & 2032

Figure 4. Trastuzumab Type Product Picture

Figure 5. Non-trastuzumab Type Product Picture

Figure 6. Global HER2 ADC Drugs for Cancer Market Value by HER2 Expression Level (US$ Million), 2021–2032

Figure 7. Global HER2 ADC Drugs for Cancer Market Share by HER2 Expression Level: 2025 vs 2032

Figure 8. HER2 Positive Product Picture

Figure 9. HER2 Low Expression Product Picture

Figure 10. Global HER2 ADC Drugs for Cancer Market Value by Antibody (US$ Million), 2021–2032

Figure 11. Global HER2 ADC Drugs for Cancer Market Share by Antibody: 2025 vs 2032

Figure 12. Monoclonal Antibody Product Picture

Figure 13. Bispecific Antibody Product Picture

Figure 14. Others Product Picture

Figure 15. Global HER2 ADC Drugs for Cancer Market Value by Application (US$ Million), 2021–2032

Figure 16. Global HER2 ADC Drugs for Cancer Market Share by Application: 2025 & 2032

Figure 17. Breast Cancer

Figure 18. Others

Figure 19. Global HER2 ADC Drugs for Cancer Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 20. Global HER2 ADC Drugs for Cancer Market Size (US$ Million), 2021–2032

Figure 21. Global HER2 ADC Drugs for Cancer Sales (K Units), 2021–2032

Figure 22. Global HER2 ADC Drugs for Cancer Average Price (US$/Unit), 2021–2032

Figure 23. HER2 ADC Drugs for Cancer Report Years Considered

Figure 24. HER2 ADC Drugs for Cancer Sales Share by Manufacturers in 2025

Figure 25. Global HER2 ADC Drugs for Cancer Revenue Share by Manufacturers in 2025

Figure 26. Top 5 and Top 10 Global HER2 ADC Drugs for Cancer Players: Market Share by Revenue in HER2 ADC Drugs for Cancer in 2025

Figure 27. HER2 ADC Drugs for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 28. Global HER2 ADC Drugs for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 29. North America HER2 ADC Drugs for Cancer Sales Market Share by Country (2021–2032)

Figure 30. North America HER2 ADC Drugs for Cancer Revenue Market Share by Country (2021–2032)

Figure 31. United States HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 32. Canada HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 33. Europe HER2 ADC Drugs for Cancer Sales Market Share by Country (2021–2032)

Figure 34. Europe HER2 ADC Drugs for Cancer Revenue Market Share by Country (2021–2032)

Figure 35. Germany HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 36. France HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 37. U.K. HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 38. Italy HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. Russia HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. Asia Pacific HER2 ADC Drugs for Cancer Sales Market Share by Region (2021–2032)

Figure 41. Asia Pacific HER2 ADC Drugs for Cancer Revenue Market Share by Region (2021–2032)

Figure 42. China HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Japan HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 44. South Korea HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 45. India HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. Australia HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. China Taiwan HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. Southeast Asia HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. Latin America HER2 ADC Drugs for Cancer Sales Market Share by Country (2021–2032)

Figure 50. Latin America HER2 ADC Drugs for Cancer Revenue Market Share by Country (2021–2032)

Figure 51. Mexico HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 52. Brazil HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 53. Argentina HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 54. Colombia HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 55. Middle East and Africa HER2 ADC Drugs for Cancer Sales Market Share by Country (2021–2032)

Figure 56. Middle East and Africa HER2 ADC Drugs for Cancer Revenue Market Share by Country (2021–2032)

Figure 57. Turkey HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 58. Saudi Arabia HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 59. UAE HER2 ADC Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032

Figure 60. Global Sales Market Share of HER2 ADC Drugs for Cancer by Type (2021–2032)

Figure 61. Global Revenue Market Share of HER2 ADC Drugs for Cancer by Type (2021–2032)

Figure 62. Global HER2 ADC Drugs for Cancer Price (US$/Unit) by Type (2021–2032)

Figure 63. Global Sales Market Share of HER2 ADC Drugs for Cancer by Application (2021–2032)

Figure 64. Global Revenue Market Share of HER2 ADC Drugs for Cancer by Application (2021–2032)

Figure 65. Global HER2 ADC Drugs for Cancer Price (US$/Unit) by Application (2021–2032)

Figure 66. HER2 ADC Drugs for Cancer Value Chain

Figure 67. Channels of Distribution (Direct Vs Distribution)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions